A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Clinical trial NCT07424833 · RECRUITING

Trial details

NCT number: NCT07424833
Sponsor: Ascentage Pharma Group Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed/Refractory Hematological Malignancies Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)Relapsed/Refractory Mantle Cell Lymphoma (MCL)Relapsed/Refractory Waldenström Macroglobulinemia (WM)Relapsed/Refractory Marginal Zone Lymphoma (MZL)Relapsed/Refractory Follicular Lymphoma (FL)

Start date: 2026-08-01
Primary completion: 2029-12-01
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.